Three items of pandemic news you may have missed recently: A tapeworm remedy to fight Covid; you can stop sanitizing now; and a new concern about blood clots with the Johnson & Johnson vaccine. Plus news briefs and a frippery. … Continue reading →
Herewith three items of pandemic news you may have missed recently: Two more Russian vaccines; a primer on T-cell immunity; and fabulous results from a real-world study of vaccine effectiveness. Plus news briefs and two fripperies. 90% effective in the … Continue reading →
Herewith three items of pandemic news you may have missed: Vitamin D levels vs. infection probability in Black people; variant viruses infecting animals; and the roller coaster that is AstraZeneca’s Phase III results announcement. Plus news briefs and a frippery. … Continue reading →
Herewith three items of pandemic news you may have missed recently: Reinfection is more likely after age 65; the EU gives AstraZeneca’s vaccine a less than resounding go-ahead; and long Covid in children. Plus news briefs and a frippery. Long … Continue reading →
Herewith three items of pandemic news you may have missed recently: Evidence that post-infection people could need only one shot; asymptomatics and long Covid; and AstraZeneca on pause across Europe over safety concerns. Plus news briefs and a frippery. AstraZeneca … Continue reading →
Herewith three items of pandemic news you may have missed recently: A caution for those scheduling mammograms around the time of vaccination; sterilizing immunity from vaccines; and peptides for prevention and treatment. Plus news briefs and a frippery. Peptides Dr. … Continue reading →
Herewith three items of pandemic news you may have missed: Concern about reinfections in Israel; evidence that the B.1.1.7 virus variant causes more serious disease; and an introduction to the newest variant from California. Plus news briefs and a frippery. … Continue reading →
Herewith three items of pandemic news you may have missed recently: A promising antiviral; a rare blood disorder perhaps related to vaccination; and the prospects for children getting vaccinated. Plus news briefs and a frippery. When will kids get vaccinated? … Continue reading →
Three items of pandemic news you may have missed recently: FDA signals a streamlined approval path for vaccine updates; South Africa halts AstraZeneca distribution; and Moderna demonstrates its shot’s efficacy against viral variants. Plus news briefs and a frippery. Moderna’s … Continue reading →
Herewith three items of pandemic news you may have missed recently: A trial of mixed shots begins in the UK; a sobering tale of a variant’s spread; and J&J applies for an EUA. Plus news briefs and a frippery. Johnson … Continue reading →
Herewith three items of pandemic news you may have missed recently: Cautionary lessons from Brazil’s second wave in Manaus; CureVac’s manufacturing partnership with Bayer; and long Covid’s entanglement with autoantibodies. Plus news briefs and a frippery. Autoantibodies and long Covid … Continue reading →
There has been a lot of noise regarding the news reports that Congressman Stephen Lynch tested positive even though he had received both doses of the Pfizer vaccine. There is nothing newsworthy there — here‘s why. Despite some clumsy reporting … Continue reading →
Herewith three items of pandemic news you may have missed recently: The South African variant shows up in the US; pharma giants are helping each other out; and Novavax reads out preliminary results. Plus news briefs and a frippery. Novavax … Continue reading →
Preliminary results are out for the J&J single-shot vaccine candidate. Efficacy against moderate and severe Covid-19 after 28 days was 72% in the US and 66% overall worldwide, and did not vary by age or race. Efficacy against severe disease … Continue reading →
Herewith three items of pandemic news you may have missed recently: Pfizer gets permission to ship fewer vials; how non-pharmaceutical interventions have varied over the course of the pandemic; and how vaccines are coping with the new virus variants. Plus … Continue reading →
